A retrospective study analysing safety of JAKi in patients with Rheumatoid Arthritis with reactivation of Herpes Zoster Virus after JAK Inhibitor
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Baricitinib (Primary) ; Tofacitinib (Primary) ; Glucocorticoids; Prednisone
- Indications Rheumatoid arthritis
- Focus Adverse reactions
Most Recent Events
- 07 Jan 2022 New trial record
- 09 Nov 2021 Results presented at the ACR Convergence 2021